// immunotherapies

eTheRNA
Immunotherapies

eTheRNA’s goal is to commercialize mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases.

To fight cancer, eTheRNA adopts multiple strategies including : 

New, pioneering immunotherapies using proprietary TriMix mRNA technology to stimulate and educate dendritic cells to create a potent, durable T-cell-mediated immune response against tumors in specific cancer indications. Different routes of administration (intranodal and intravenous) and different sources of antigens (tumor-associated antigens, viral antigens and shared neoantigens) are being deployed in different combinations in multiple development programs.

An innovative mRNA mix that mimics the action of oncolytic viruses to induce immunogenic death of tumour cells and renders the tumour more susceptible towards the anti-tumour T cell response

The different approaches can be combined with each other and other classes of treatment interventions.

To fight infectious diseases, eTheRNA is adapting its proprietary

TriMix technology to a product that can be administered intranasally or intramuscularly and lead to antigen-specific T-cell-mediated mucosal immunity. This new approach is being applied to vaccines to protect against upper respiratory tract viruses including SARS-CoV-2 (coronavirus).

eTheRNA Pipeline Overview

Project Code

Project Name

Indication

Stage

[Preclinical, Clinical Phase I, Clinical Phase II, Clinical Phase III, Commercial]

Mode

Administration

Oncology

A001

IN naked mRNA vaccine for melanoma

Metastatic melanoma

Clinical: Phase I / II

Therapeutic vaccine

Intranodal

A002

LNP based E6-E7 vaccine

HPV+ cancers

Preclinical

Therapeutic vaccine

Intravenous

A034

Oncolytic mRNA mix

Solid tumour

Preclinical

Oncolytic

Intrathecal

A005

Frameshifted NeoAgs

Metastatic renal cell carcinoma

Preclinical

Therapeutic vaccine

Intravenous

Infectious Disease

A006

NoseVAx

Respiratory viruses

Preclinical

Prophylactic vaccine

Intramuscular


A007

-

Malaria

Preclinical

Prophylactic vaccine

Intramuscular


A008

-

HIV

Preclinical

Prophylactic vaccine

Intramuscular

Technology

Platform expansion

ID / autoimmune

-

-

-

Galileilaan 19, 2845 Niel, Belgium

Our Address

Our Mailbox

+32 3 369 17 40

Our Phone

© 2020 Etherna | Studio Hanswijk